USPTO serial 87304368
MEIRAGTX
Reviewed by CopyMark Law Group
Reg. 5527437Status 710
- Filing date
- Status date
- Registration date
- Jul 31, 2018
- Examiner
- ROSEN, AMANDA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with MEIRAGTX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael J. Leonard
MICHAEL J. LEONARD FOX ROTHSCHILD LLP997 LENOX DRIVE, BLDG. 3LAWRENCEVILLE, NJ 08648-2311UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical additives, namely, chemical auxiliary agents, carriers and substances for use in the manufacture of pharmaceutical preparations | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical products for use in gene therapy; pharmaceutical and biological preparations for the treatment of neurological and neurodegerative diseases, ocular diseases and rare diseases, in the nature of rare kidney diseases, rare cardiovascular diseases, rare hepato-gastro-enterological diseases, rare immunodeficiencies, developmental defects, neuromuscular diseases, rare neurological diseases, rare cardiovascular diseases, rare lung diseases, rare bone diseases, rare sensory disorders, rare skin diseases, rare diseases of connective tissue, rare endocrine diseases, rare hereditary metabolic diseases, rare nonmalignant hematologic disorders; pharmaceutical preparations, namely, anti-infectives, anti-inflammatories, antibacterial pharmaceuticals, antibiotics, antifungal preparations, antivirals; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; dermatological pharmaceutical products; pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases | SECTION 8 - CANCELLED | — |
| 040 | Custom manufacture of human therapeutics, pharmaceuticals, biologicals and biopharmaceuticals | SECTION 8 - CANCELLED | — |
| 042 | Scientific research in the field of genetics, gene therapy and genetic engineering; Genetic testing for scientific research purposes; scientific advisory services relating to gene therapy research; Scientific, biological, pharmaceutical and medical research and services; laboratory research in the fields of genetics, drug development, biotechnology, microbiology and molecular biology; biochemical and biotechnological analysis and services | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MeiraGTx Limited
- Other trademarks owned by MeiraGTx Limited
- Other trademarks owned by MeiraGTx Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named MEIRAGTX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 14, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jul 31, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jul 31, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 15, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 15, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 25, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 12, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 9, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 9, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 5, 2018 | ALIE | ASSIGNED TO LIE | — |
| Mar 23, 2018 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 25, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 25, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 25, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 6, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 5, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 5, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 12, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 12, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 12, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 12, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 25, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 20, 2017 | NWAP | NEW APPLICATION ENTERED | — |